Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cassava Sciences has announced its participation in the H.C. Wainwright 24^th Annual Global Investment Conference in New York on September 13, 2022. President & CEO Remi Barbier will present in person from 3:30 PM to 4:00 PM Eastern Time. Institutional investors can request meetings through the conference's official site. A live webcast of the presentation will be available on Cassava's investors page, with an archived replay accessible for 90 days afterward. The company is focused on treating Alzheimer’s disease with its lead candidate simufilam.

AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24^th Annual Global Investment Conference, being held in New York.

Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.

Event details follow:
Date: Tuesday, September 13^th
Time: 3:30pm to 4:00 Eastern Time
Webcast: https://journey.ct.events/view/ffcd827b-9de0-4b05-a6fd-5ea79810a3ee

A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com. An archived replay will be available for 90 days following the event.

About Cassava Sciences, Inc.

Cassava Sciences Inc. is a clinical stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer's disease dementia, in a large Phase 3 clinical program under Special Protocol Assessments from the FDA.

FAQ

What is the date and time of Cassava Sciences' presentation at the H.C. Wainwright conference?

Cassava Sciences will present on September 13, 2022, from 3:30 PM to 4:00 PM Eastern Time.

Who is presenting for Cassava Sciences at the conference?

Remi Barbier, the President & CEO, will present at the conference.

Where can I find the webcast for Cassava Sciences' presentation?

The live webcast can be found on the 'Investors' page of Cassava Sciences' website.

How long will the archived webcast of the presentation be available?

The archived webcast will be available for 90 days following the event.

What is the main focus of Cassava Sciences' research?

Cassava Sciences focuses on detecting and treating neurodegenerative diseases, particularly Alzheimer’s disease.

What is simufilam?

Simufilam is Cassava Sciences' lead drug candidate for treating Alzheimer's disease dementia, currently in a Phase 3 clinical program.